Jeonjin Biopharm, 1.8 Billion KRW Paid-in Capital Increase Targeting Yuhan Corporation
[Asia Economy Reporter Jang Hyowon] Jeonjin Bio Pharm announced on the 30th that it has decided on a third-party allotment paid-in capital increase worth 1.8 billion KRW targeting Yuhan Corporation.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- Targeting China’s 5,700 Trillion Won Silver Market: K-Bio One Team Accelerates Local Expansion
- "Reporters Who First Revealed Jo Jinwoong's Juvenile Offense History Cleared of Juvenile Act Violation"
- Instead of a National Assembly Profile, Now a 'Carpenter'... Ryu Hojung Says "I Couldn't Do a Body Profile Shoot Twice"
Of the raised funds, 1 billion KRW will be used for facility investment, and 800 million KRW will be used for operating expenses. The issue price per new share is 3,605 KRW.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
